Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

被引：13
作者：
Barnet, Megan B. [1 ,2 ,3 ]
Cooper, Wendy A. [3 ,4 ,5 ]
Boyer, Michael J. [3 ,6 ]
Kao, Steven [3 ,6 ]
机构：
[1] Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia
[2] Univ New South Wales, Grad Res Sch, Sydney, NSW 2052, Australia
[3] Univ Sydney, Sydney Med Sch, Camperdown, NSW 2006, Australia
[4] Royal Prince Alfred Hosp, Camperdown, NSW 2006, Australia
[5] Western Sydney Univ, Sch Med, Penrith, NSW 2751, Australia
[6] Chris OBrien Lifehouse, Camperdown, NSW 2006, Australia
来源：
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 06期
关键词：
non-small cell lung cancer; immunotherapy; checkpoint inhibitors; MAINTENANCE THERAPY; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB; ANTIBODY; NECROSIS; PLACEBO;
D O I：
10.3390/jcm7060151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where best-case scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.
引用
收藏
页数：14
相关论文
共 51 条
  • [1] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [2] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [3] A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
    Alfonso, Sailyn
    Valdes-Zayas, Anet
    Santiesteban, Eduardo R.
    Flores, Yoanna I.
    Areces, Fernando
    Hernandez, Maurenis
    Viada, Carmen E.
    Mendoza, Ivis C.
    Guerra, Pedro P.
    Garcia, Elena
    Ortiz, Ramon A.
    de la Torre, Ana V.
    Cepeda, Meylan
    Perez, Kirenia
    Chong, Eric
    Maria Hernandez, Ana
    Toledo, Darien
    Gonzalez, Zuyen
    Mazorra, Zaima
    Crombet, Tania
    Perez, Rolando
    Maria Vazquez, Ana
    Macias, Amparo E.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (14) : 3660 - 3671
  • [4] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
    Allen, Elizabeth
    Jabouille, Arnaud
    Rivera, Lee B.
    Lodewijckx, Inge
    Missiaen, Rindert
    Steri, Veronica
    Feyen, Kevin
    Tawney, Jaime
    Hanahan, Douglas
    Michael, Iacovos P.
    Bergers, Gabriele
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)
  • [5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [6] Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
    Apetoh, L.
    Ladoire, S.
    Coukos, G.
    Ghiringhelli, F.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (09) : 1813 - 1823
  • [7] Tumour necrosis factor and cancer
    Balkwill, Frances
    [J]. NATURE REVIEWS CANCER, 2009, 9 (05) : 361 - 371
  • [8] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [9] Brahmer J.R., 2017, P WORLD C LUNG CANC
  • [10] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
123456